| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ... New England journal of medicine 352 (10), 987-996, 2005 | 22319 | 2005 |
| MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma ME Hegi, AC Diserens, T Gorlia, MF Hamou, N De Tribolet, M Weller, ... New England Journal of Medicine 352 (10), 997-1003, 2005 | 8358 | 2005 |
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the … R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ... The lancet oncology 10 (5), 459-466, 2009 | 8032 | 2009 |
| Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma J Dalmau, E Tüzün, H Wu, J Masjuan, JE Rossi, A Voloschin, ... Annals of neurology 61 (1), 25-36, 2007 | 3038 | 2007 |
| Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ... New England Journal of Medicine 370 (8), 709-722, 2014 | 2634 | 2014 |
| European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and … R Stupp, WP Mason, MJ Van den Bent, M Weller, B Fisher, MJ Taphoorn, ... N Engl J Med 352 (10), 987-996, 2005 | 1042* | 2005 |
| European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of … R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ... Lancet Oncol 10 (5), 459-466, 2009 | 1005 | 2009 |
| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 999 | 2017 |
| Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma R Vitaliani, W Mason, B Ances, T Zwerdling, Z Jiang, J Dalmau Annals of Neurology: Official Journal of the American Neurological …, 2005 | 794 | 2005 |
| Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of … M Petit-Pedrol, T Armangue, X Peng, L Bataller, T Cellucci, R Davis, ... The lancet neurology 13 (3), 276-286, 2014 | 626 | 2014 |
| Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial RO Mirimanoff, T Gorlia, W Mason, MJ Van den Bent, RD Kortmann, ... J Clin Oncol 24 (16), 2563-2569, 2006 | 625 | 2006 |
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ... Journal of Clinical Oncology 31 (26), 3212, 2013 | 587 | 2013 |
| Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma W Wick, VK Puduvalli, MC Chamberlain, MJ Van Den Bent, AF Carpentier, ... Journal of clinical oncology 28 (7), 1168, 2010 | 566 | 2010 |
| Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study BG Baumert, ME Hegi, MJ van den Bent, A von Deimling, T Gorlia, ... The Lancet Oncology 17 (11), 1521-1532, 2016 | 486 | 2016 |
| Changing paradigms—an update on the multidisciplinary management of malignant glioma R Stupp, ME Hegi, MJ Van Den Bent, WP Mason, M Weller, ... The oncologist 11 (2), 165-180, 2006 | 485 | 2006 |
| Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. F Graus, J Dalmou, R Rene, M Tora, N Malats, JJ Verschuuren, ... Journal of Clinical Oncology 15 (8), 2866-2872, 1997 | 447 | 1997 |
| Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study JR Perry, K Bélanger, WP Mason, D Fulton, P Kavan, J Easaw, C Shields, ... J Clin Oncol 28 (12), 2051-2057, 2010 | 420 | 2010 |
| Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. WP Mason, F Graus, B Lang, J Honnorat, JY Delattre, F Valldeoriola, ... Brain: a journal of neurology 120 (8), 1279-1300, 1997 | 397 | 1997 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 364 | 2017 |
| Health-related quality of life in patients with glioblastoma: a randomised controlled trial MJB Taphoorn, R Stupp, C Coens, D Osoba, R Kortmann, ... The lancet oncology 6 (12), 937-944, 2005 | 360 | 2005 |
perry juniversity of torontoVerified email at sunnybrook.ca
